Type 1 diabetes (T1D) is characterized by the autoimmune destruction of the insulin secreting β-cells, with consequent aberrant blood glucose levels. Hyperglycemia is the common denominator for most of the chronic diabetic vascular complications, which represent the main cause of life reduction in T1D patients. For this disease, three interlaced medical needs remain: understanding the underlying mechanisms involved in pancreatic β-cell loss; identifying biomarkers able to predict T1D progression and its related complications; recognizing novel therapeutic targets.
Recent Advances:
Extracellular vesicles (EVs), released by most cell types, were discovered to contain a plethora of different molecules (including microRNAs) with regulatory properties, which are emerging as mediators of cell-to-cell communication at the paracrine and endocrine level. Recent knowledge suggests that EVs may act as pathogenic factors, and be developed into disease biomarkers and therapeutic targets in the context of several human diseases.
Critical Issues:
EVs have been recently shown to sustain a dysregulated cellular crosstalk able to exacerbate the autoimmune response in the pancreatic islets of T1D; moreover, EVs were shown to be able to monitor and/or predict the progression of T1D and the insurgence of vasculopathies.
Future Directions:
More mechanistic studies are needed to investigate whether the dysregulation of EVs in T1D patients is solely reflecting the progression of diabetes and related complications, or EVs also directly participate in the disease process, thus pointing to a potential use of EVs as therapeutic targets/tools in T1D. Antioxid. Redox Signal. 36, 631–651.
Get full access to this article
View all access options for this article.
References
1.
AbelsER and BreakefieldXO. Introduction to extracellular vesicles: biogenesis, RNA cargo selection, content, release, and uptake. Cell Mol Neurobiol, 36: 301–312, 2016.
2.
Adamsson ErydS, SvenssonAM, FranzenS, EliassonB, NilssonPM, and GudbjornsdottirS. Risk of future microvascular and macrovascular disease in people with type 1 diabetes of very long duration: a national study with 10-year follow-up. Diabet Med, 34: 411–418, 2017.
3.
AdmyreC, BohleB, JohanssonSM, Focke-TejklM, ValentaR, ScheyniusA, and GabrielssonS. B cell-derived exosomes can present allergen peptides and activate allergen-specific T cells to proliferate and produce TH2-like cytokines. J Allergy Clin Immunol, 120: 1418–1424, 2007.
4.
AlRashidiFT and GillespieKM. Biomarkers in islet cell transplantation for type 1 diabetes. Curr Diab Rep, 18: 94, 2018.
5.
ArnushM, ScarimAL, HeitmeierMR, KellyCB, and CorbettJA. Potential role of resident islet macrophage activation in the initiation of autoimmune diabetes. J Immunol, 160: 2684–2691, 1998.
6.
AssmannTS, Recamonde-MendozaM, De SouzaBM, and CrispimD. MicroRNA expression profiles and type 1 diabetes mellitus: systematic review and bioinformatic analysis. Endocr Connect, 6: 773–790, 2017.
7.
Balzano-NogueiraL, RamirezR, ZamkovayaT, DaileyJ, ArdissoneAN, ChamalaS, Serrano-QuílezJ, RubioT, HallerMJ, ConcannonP, AtkinsonMA, SchatzDA, TriplettEW, and ConesaA. Integrative analyses of TEDDY Omics data reveal lipid metabolism abnormalities, increased intracellular ROS and heightened inflammation prior to autoimmunity for type 1 diabetes. Genome Biol, 22: 39, 2021.
8.
BarrettEJ, LiuZ, KhamaisiM, KingGL, KleinR, KleinBEK, HughesTM, CraftS, FreedmanBI, BowdenDW, VinikAI, and CaselliniCM. Diabetic microvascular disease: an Endocrine Society scientific statement. J Clin Endocrinol Metab, 102: 4343–4410, 2017.
9.
BartelDP.MicroRNAs: target recognition and regulatory functions. Cell, 136: 215–233, 2009.
BaruttaF, BrunoG, MatulloG, ChaturvediN, GrimaldiS, SchalkwijkC, StehouwerCD, FullerJH, and GrudenG. MicroRNA-126 and micro-/macrovascular complications of type 1 diabetes in the EURODIAB Prospective Complications Study. Acta Diabetol, 54: 133–139, 2017.
BashratyanR, ShengH, RegnD, RahmanMJ, and DaiYD. Insulinoma-released exosomes activate autoreactive marginal zone-like B cells that expand endogenously in prediabetic NOD mice. Eur J Immunol, 43: 2588–2597, 2013.
14.
BebuI, SchadeD, BraffettB, KosiborodM, Lopes-VirellaM, SolimanEZ, HermanWH, BluemkeDA, WalliaA, OrchardT, and Lachin JM; DCCT/EDIC ResearchGroup. Risk factors for first and subsequent CVD events in type 1 diabetes: the DCCT/EDIC Study. Diabetes Care, 43: 867–874, 2020.
15.
BergenK, MobarrezF, JorneskogG, WallenH, and TehraniS. High levels of endothelial and platelet microvesicles in patients with type 1 diabetes irrespective of microvascular complications. Thromb Res, 196: 78–86, 2020.
16.
BjornstadP, DonaghueKC, and MaahsDM. Macrovascular disease and risk factors in youth with type 1 diabetes: time to be more attentive to treatment?. Lancet Diabetes Endocrinol, 6: 809–820, 2018.
17.
BlanchardN, LankarD, FaureF, RegnaultA, DumontC, RaposoG, and HivrozC. TCR activation of human T cells induces the production of exosomes bearing the TCR/CD3/zeta complex. J Immunol, 168: 3235–3241, 2002.
18.
BoultonAJ, VinikAI, ArezzoJC, BrilV, FeldmanEL, FreemanR, MalikRA, MaserRE, SosenkoJM, and Ziegler D; American DiabetesAssociation. Diabetic neuropathies: a statement by the American Diabetes Association. Diabetes Care, 28: 956–962, 2005.
19.
BronevetskyY and AnselKM. Regulation of miRNA biogenesis and turnover in the immune system. Immunol Rev, 253: 304–316, 2013.
20.
BrownleeM.Biochemistry and molecular cell biology of diabetic complications. Nature, 414: 813–820, 2001.
21.
BurgerD, TurnerM, XiaoF, MunkondaMN, AkbariS, and BurnsKD. High glucose increases the formation and pro-oxidative activity of endothelial microparticles. Diabetologia, 60: 1791–1800, 2017.
22.
CaiZ, ZhangW, YangF, YuL, YuZ, PanJ, WangL, CaoX, and WangJ. Immunosuppressive exosomes from TGF-beta1 gene-modified dendritic cells attenuate Th17-mediated inflammatory autoimmune disease by inducing regulatory T cells. Cell Res, 22: 607–610, 2012.
23.
CameronNE, EatonSE, CotterMA, and TesfayeS. Vascular factors and metabolic interactions in the pathogenesis of diabetic neuropathy. Diabetologia, 44: 1973–1988, 2001.
24.
CaporaliA, MeloniM, NailorA, MiticT, ShantikumarS, RiuF, Sala-NewbyGB, RoseL, BesnierM, KatareR, VoellenkleC, VerkadeP, MartelliF, MadedduP, and EmanueliC. p75(NTR)-dependent activation of NF-kappaB regulates microRNA-503 transcription and pericyte-endothelial crosstalk in diabetes after limb ischaemia. Nat Commun, 6: 8024, 2015.
25.
CerielloA.New insights on oxidative stress and diabetic complications may lead to a “causal” antioxidant therapy. Diabetes Care, 26: 1589–1596, 2003.
26.
CerielloA.The emerging challenge in diabetes: the “metabolic memory.”. Vascul Pharmacol, 57: 133–138, 2012.
27.
ChahedS, LeroyerAS, BenzerrougM, GaucherD, GeorgescuA, PicaudS, SilvestreJS, GaudricA, TedguiA, MassinP, and BoulangerCM. Increased vitreous shedding of microparticles in proliferative diabetic retinopathy stimulates endothelial proliferation. Diabetes, 59: 694–701, 2010.
ChenJ, ChernatynskayaAV, LiJW, KimbrellMR, CassidyRJ, PerryDJ, MuirAB, AtkinsonMA, BruskoTM, and MathewsCE. T cells display mitochondria hyperpolarization in human type 1 diabetes. Sci Rep, 7: 10835, 2017.
30.
ChenJ, StimpsonSE, Fernandez-BuenoGA, and MathewsCE. Mitochondrial reactive oxygen species and type 1 diabetes. Antioxid Redox Signal, 29: 1361–1372, 2018.
31.
ChironiG, SimonA, HugelB, Del PinoM, GariepyJ, FreyssinetJM, and TedguiA. Circulating leukocyte-derived microparticles predict subclinical atherosclerosis burden in asymptomatic subjects. Arterioscler Thromb Vasc Biol, 26: 2775–2780, 2006.
32.
Chiva-BlanchG, SuadesR, PadroT, VilahurG, PenaE, YbarraJ, PouJM, and BadimonL. Microparticle shedding by erythrocytes, monocytes and vascular smooth muscular cells is reduced by aspirin in diabetic patients. Rev Esp Cardiol (Engl Ed), 69: 672–680, 2016.
33.
ChoS, WuCJ, YasudaT, CruzLO, KhanAA, LinLL, NguyenDT, MillerM, LeeHM, KuoML, BroideDH, RajewskyK, RudenskyAY, and LuLF. miR-23 approximately 27 approximately 24 clusters control effector T cell differentiation and function. J Exp Med, 213: 235–249, 2016.
34.
ChoudhuriK, LlodraJ, RothEW, TsaiJ, GordoS, WucherpfennigKW, KamLC, StokesDL, and DustinML. Polarized release of T-cell-receptor-enriched microvesicles at the immunological synapse. Nature, 507: 118–123, 2014.
35.
ChristerssonC, LindahlB, and SiegbahnA. The composition and daily variation of microparticles in whole blood in stable coronary artery disease. Scand J Clin Lab Invest, 76: 25–32, 2016.
36.
CianciarusoC, PhelpsEA, PasquierM, HamelinR, DemurtasD, Alibashe AhmedM, PiemontiL, HirosueS, SwartzMA, De PalmaM, HubbellJA, and BaekkeskovS. Primary human and rat β-cells release the intracellular autoantigens GAD65, IA-2, and proinsulin in exosomes together with cytokine-induced enhancers of immunity. Diabetes, 66: 460–473, 2017.
37.
ColinoJ and SnapperCM. Exosomes from bone marrow dendritic cells pulsed with diphtheria toxoid preferentially induce type 1 antigen-specific IgG responses in naive recipients in the absence of free antigen. J Immunol, 177: 3757–3762, 2006.
38.
CooperME, El-OstaA, AllenTJ, WatsonAMD, ThomasMC, and Jandeleit-DahmKAM. Metabolic Karma-the atherogenic legacy of diabetes: the 2017 Edwin Bierman Award Lecture. Diabetes, 67: 785–790, 2018.
39.
CostacouT, EdmundowiczD, PrinceC, ConwayB, and OrchardTJ. Progression of coronary artery calcium in type 1 diabetes mellitus. Am J Cardiol, 100: 1543–1547, 2007.
40.
DarwicheR, ChongMM, SantamariaP, ThomasHE, and KayTW. Fas is detectable on beta cells in accelerated, but not spontaneous, diabetes in nonobese diabetic mice. J Immunol, 170: 6292–6297, 2003.
41.
DasuMR, DevarajS, ZhaoL, HwangDH, and JialalI. High glucose induces toll-like receptor expression in human monocytes: mechanism of activation. Diabetes, 57: 3090–3098, 2008.
42.
DaviesMJ, D'AlessioDA, FradkinJ, KernanWN, MathieuC, MingroneG, RossingP, TsapasA, WexlerDJ, and BuseJB. Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia, 61: 2461–2498, 2018.
43.
de CandiaP, TorriA, GorlettaT, FedeliM, BulgheroniE, CheroniC, MarabitaF, CrostiM, MoroM, ParianiE, RomanoL, EspositoS, MoscaF, RossettiG, RossiRL, GeginatJ, CasoratiG, DellabonaP, PaganiM, and AbrignaniS. Intracellular modulation, extracellular disposal and serum increase of MiR-150 mark lymphocyte activation. PLoS One, 8: e75348, 2013.
44.
de JongVM, van der SlikAR, LabanS, van ‘t SlotR, KoelemanBP, ZaldumbideA, and RoepBO. Survival of autoreactive T lymphocytes by microRNA-mediated regulation of apoptosis through TRAIL and Fas in type 1 diabetes. Genes Immun, 17: 342–348, 2016.
45.
De ToroJ, HerschlikL, WaldnerC, and MonginiC. Emerging roles of exosomes in normal and pathological conditions: new insights for diagnosis and therapeutic applications. Front Immunol, 6: 203, 2015.
46.
de ZeeuwD, BekkerP, HenkelE, HasslacherC, Gouni-BertholdI, MehlingH, PotarcaA, TesarV, HeerspinkHJ, and SchallTJ;
CCX140-B Diabetic Nephropathy Study Group. The effect of CCR2 inhibitor CCX140-B on residual albuminuria in patients with type 2 diabetes and nephropathy: a randomised trial. Lancet Diabetes Endocrinol, 3: 687–696, 2015.
47.
DevarajS, GlaserN, GriffenS, Wang-PolagrutoJ, MiguelinoE, and JialalI. Increased monocytic activity and biomarkers of inflammation in patients with type 1 diabetes. Diabetes, 55: 774–779, 2006.
48.
DiamantM, NieuwlandR, PabloRF, SturkA, SmitJW, and RadderJK. Elevated numbers of tissue-factor exposing microparticles correlate with components of the metabolic syndrome in uncomplicated type 2 diabetes mellitus. Circulation, 106: 2442–2447, 2002.
49.
DingX, JingN, ShenA, GuoF, SongY, PanM, MaX, ZhaoL, ZhangH, WuL, QinG, and ZhaoY. miR-21-5p in macrophage-derived extracellular vesicles affects podocyte pyroptosis in diabetic nephropathy by regulating A20. J Endocrinol Invest, 44: 1175–1184, 2021.
50.
DiPetrilloK, CoutermarshB, and GesekFA. Urinary tumor necrosis factor contributes to sodium retention and renal hypertrophy during diabetes. Am J Physiol Renal Physiol, 284: F113–F121, 2003.
51.
DronavalliS, DukaI, and BakrisGL. The pathogenesis of diabetic nephropathy. Nat Clin Pract Endocrinol Metab, 4: 444–452, 2008.
52.
DudekNL, ThomasHE, MarianaL, SutherlandRM, AllisonJ, EstellaE, AngstetraE, TrapaniJA, SantamariaP, LewAM, and KayTW. Cytotoxic T-cells from T-cell receptor transgenic NOD8.3 mice destroy beta-cells via the perforin and Fas pathways. Diabetes, 55: 2412–2418, 2006.
EisenbarthGS.Type I diabetes mellitus. A chronic autoimmune disease. N Engl J Med, 314: 1360–1368, 1986.
55.
EizirikDL, ColliML, and OrtisF. The role of inflammation in insulitis and β-cell loss in type 1 diabetes. Nat Rev Endocrinol, 5: 219–226, 2009.
56.
EliassonL and EsguerraJL. Role of non-coding RNAs in pancreatic beta-cell development and physiology. Acta Physiol (Oxf), 211: 273–284, 2014.
57.
ErenerS, MarwahaA, TanR, PanagiotopoulosC, and KiefferTJ. Profiling of circulating microRNAs in children with recent onset of type 1 diabetes. JCI Insight, 2: e89656, 2017.
58.
EstellaE, McKenzieMD, CatterallT, SuttonVR, BirdPI, TrapaniJA, KayTW, and ThomasHE. Granzyme B-mediated death of pancreatic beta-cells requires the proapoptotic BH3-only molecule bid. Diabetes, 55: 2212–2219, 2006.
59.
FanB, LiC, SzaladA, WangL, PanW, ZhangR, ChoppM, ZhangZG, and LiuXS. Mesenchymal stromal cell-derived exosomes ameliorate peripheral neuropathy in a mouse model of diabetes. Diabetologia, 63: 431–443, 2020.
60.
FavaroE, CarpanettoA, CaorsiC, GiovarelliM, AngeliniC, Cavallo-PerinP, TettaC, CamussiG, and ZanoneMM. Human mesenchymal stem cells and derived extracellular vesicles induce regulatory dendritic cells in type 1 diabetic patients. Diabetologia, 59: 325–333, 2016.
61.
FordhamJB, NaqviAR, and NaresS. miR-24 regulates macrophage polarization and plasticity. J Clin Cell Immunol, 6: 362, 2015.
62.
FriedmanRC, FarhKK, BurgeCB, and BartelDP. Most mammalian mRNAs are conserved targets of microRNAs. Genome Res, 19: 92–105, 2009.
63.
FuQ, JiangH, WangZ, WangX, ChenH, ShenZ, XiaoL, GuoX, and YangT. Injury factors alter miRNAs profiles of exosomes derived from islets and circulation. Aging (Albany NY), 10: 3986–3999, 2018.
64.
GacebA, MartinezMC, and AndriantsitohainaR. Extracellular vesicles: new players in cardiovascular diseases. Int J Biochem Cell Biol, 50: 24–28, 2014.
65.
GaleEA.Type 1 diabetes in the young: the harvest of sorrow goes on. Diabetologia, 48: 1435–1438, 2005.
66.
GaoW, LiuH, YuanJ, WuC, HuangD, MaY, ZhuJ, MaL, GuoJ, ShiH, ZouY, and GeJ. Exosomes derived from mature dendritic cells increase endothelial inflammation and atherosclerosis via membrane TNF-alpha mediated NF-kappaB pathway. J Cell Mol Med, 20: 2318–2327, 2016.
67.
GaravelliS, BruzzanitiS, TagliabueE, Di SilvestreD, PrattichizzoF, MozzilloE, FattorussoV, La SalaL, CerielloA, PucaAA, MauriP, StrolloR, MariglianoM, MaffeisC, PetrelliA, BosiE, FranzeseA, GalganiM, MatareseG, and de CandiaP. Plasma circulating miR-23 ∼ 27 ∼ 24 clusters correlate with the immunometabolic derangement and predict C-peptide loss in children with type 1 diabetes. Diabetologia, 63: 2699–2712, 2020.
68.
GaravelliS, BruzzanitiS, TagliabueE, PrattichizzoF, Di SilvestreD, PernaF, La SalaL, CerielloA, MozzilloE, FattorussoV, MauriP, PucaAA, FranzeseA, MatareseG, GalganiM, and de CandiaP. Blood co-circulating extracellular microRNAs and immune cell subsets associate with type 1 diabetes severity. Int J Mol Sci, 21: 477, 2020.
GeraldesP and KingGL. Activation of protein kinase C isoforms and its impact on diabetic complications. Circ Res, 106: 1319–1331, 2010.
71.
GhaiV, WuX, Bheda-MalgeA, ArgyropoulosCP, BernardoJF, OrchardT, GalasD, and WangK. Genome-wide profiling of urinary extracellular vesicle microRNAs associated with diabetic nephropathy in type 1 diabetes. Kidney Int Rep, 3: 555–572, 2018.
GrangeC, TrittaS, TapparoM, CedrinoM, TettaC, CamussiG, and BrizziMF. Stem cell-derived extracellular vesicles inhibit and revert fibrosis progression in a mouse model of diabetic nephropathy. Sci Rep, 9: 4468, 2019.
74.
GreenbaumCJ, BeamCA, BoulwareD, GitelmanSE, GottliebPA, HeroldKC, LachinJM, McGeeP, PalmerJP, PescovitzMD, Krause-SteinraufH, SkylerJS, and SosenkoJM;
Type 1 Diabetes TrialNet Study Group. Fall in C-peptide during first 2 years from diagnosis: evidence of at least two distinct phases from composite Type 1 Diabetes TrialNet data. Diabetes, 61: 2066–2073, 2012.
75.
GriecoFA, SebastianiG, Juan-MateuJ, VillateO, MarroquiL, LadriereL, TugayK, RegazziR, BuglianiM, MarchettiP, DottaF, and EizirikDL. MicroRNAs miR-23a-3p, miR-23b-3p, and miR-149-5p regulate the expression of proapoptotic BH3-only proteins DP5 and PUMA in human pancreatic beta-cells. Diabetes, 66: 100–112, 2017.
76.
GuayC, JacovettiC, NescaV, MotterleA, TugayK, and RegazziR. Emerging roles of non-coding RNAs in pancreatic β-cell function and dysfunction. Diabetes Obes Metab 14(Suppl, 3): 12–21, 2012.
77.
GuayC, KruitJK, RomeS, MenoudV, MulderNL, JurdzinskiA, MancarellaF, SebastianiG, DondaA, GonzalezBJ, JandusC, BouzakriK, PingetM, BoitardC, RomeroP, DottaF, and RegazziR. Lymphocyte-derived exosomal microRNAs promote pancreatic beta cell death and may contribute to type 1 diabetes development. Cell Metab, 29: 348.e6–361.e6, 2019.
78.
GulinelliS, SalaroE, VuerichM, BozzatoD, PizziraniC, BolognesiG, IdzkoM, Di VirgilioF, and FerrariD. IL-18 associates to microvesicles shed from human macrophages by a LPS/TLR-4 independent mechanism in response to P2X receptor stimulation. Eur J Immunol, 42: 3334–3345, 2012.
79.
HafianeA and DaskalopoulouSS. Extracellular vesicles characteristics and emerging roles in atherosclerotic cardiovascular disease. Metabolism, 85: 213–222, 2018.
80.
HardingC, HeuserJ, and StahlP. Receptor-mediated endocytosis of transferrin and recycling of the transferrin receptor in rat reticulocytes. J Cell Biol, 97: 329–339, 1983.
81.
HasiloCP, NegiS, AllaeysI, CloutierN, RutmanAK, GasparriniM, BonneilE, ThibaultP, BoilardE, and ParaskevasS. Presence of diabetes autoantigens in extracellular vesicles derived from human islets. Sci Rep, 7: 5000, 2017.
82.
HeL and HannonGJ. MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet, 5: 522–531, 2004.
83.
HombrebuenoJR, CairnsL, DuttonLR, LyonsTJ, BrazilDP, MoynaghP, CurtisTM, and XuH. Uncoupled turnover disrupts mitochondrial quality control in diabetic retinopathy. JCI Insight, 4: e129760, 2019.
84.
HuangC, FisherKP, HammerSS, NavitskayaS, BlanchardGJ, and BusikJV. Plasma exosomes contribute to microvascular damage in diabetic retinopathy by activating the classical complement pathway. Diabetes, 67: 1639–1649, 2018.
85.
HuangX, YuanT, TschannenM, SunZ, JacobH, DuM, LiangM, DittmarRL, LiuY, LiangM, KohliM, ThibodeauSN, BoardmanL, and WangL. Characterization of human plasma-derived exosomal RNAs by deep sequencing. BMC Genomics, 14: 319, 2013.
86.
InselRA, DunneJL, AtkinsonMA, ChiangJL, DabeleaD, GottliebPA, GreenbaumCJ, HeroldKC, KrischerJP, LernmarkA, RatnerRE, RewersMJ, SchatzDA, SkylerJS, SosenkoJM, and ZieglerAG. Staging presymptomatic type 1 diabetes: a scientific statement of JDRF, the Endocrine Society, and the American Diabetes Association. Diabetes Care, 38: 1964–1974, 2015.
87.
JansenF, YangX, FranklinBS, HoelscherM, SchmitzT, BedorfJ, NickenigG, and WernerN. High glucose condition increases NADPH oxidase activity in endothelial microparticles that promote vascular inflammation. Cardiovasc Res, 98: 94–106, 2013.
88.
JansenF, YangX, HoelscherM, CattelanA, SchmitzT, ProebstingS, WenzelD, VosenS, FranklinBS, FleischmannBK, NickenigG, and WernerN. Endothelial microparticle-mediated transfer of MicroRNA-126 promotes vascular endothelial cell repair via SPRED1 and is abrogated in glucose-damaged endothelial microparticles. Circulation, 128: 2026–2038, 2013.
89.
JayachandranM, LitwillerRD, OwenWG, HeitJA, BehrenbeckT, MulvaghSL, AraozPA, BudoffMJ, HarmanSM, and MillerVM. Characterization of blood borne microparticles as markers of premature coronary calcification in newly menopausal women. Am J Physiol Heart Circ Physiol, 295: H931–H938, 2008.
JiangZZ, LiuYM, NiuX, YinJY, HuB, GuoSC, FanY, WangY, and WangNS. Exosomes secreted by human urine-derived stem cells could prevent kidney complications from type I diabetes in rats. Stem Cell Res Ther, 7: 24, 2016.
92.
JonesS, JonesS, and PhillipsAO. Regulation of renal proximal tubular epithelial cell hyaluronan generation: implications for diabetic nephropathy. Kidney Int, 59: 1739–1749, 2001.
93.
JunH-S, YoonC-S, ZbytnuikL, van RooijenN, and YoonJ-W. The role of macrophages in T cell–mediated autoimmune diabetes in nonobese diabetic mice. J Exp Med, 189: 347–358, 1999.
94.
KalaniA, MohanA, GodboleMM, BhatiaE, GuptaA, SharmaRK, and TiwariS. Wilm's tumor-1 protein levels in urinary exosomes from diabetic patients with or without proteinuria. PLoS One, 8: e60177, 2013.
95.
KamaldenTA, Macgregor-DasAM, KannanSM, Dunkerly-EyringB, KhaliddinN, XuZ, FuscoAP, YazibSA, ChowRC, DuhEJ, HalushkaMK, SteenbergenC, and DasS. Exosomal microRNA-15a transfer from the pancreas augments diabetic complications by inducing oxidative stress. Antioxid Redox Signal, 27: 913–930, 2017.
96.
Kandere-GrzybowskaK, LetourneauR, KempurajD, DonelanJ, PoplawskiS, BoucherW, AthanassiouA, and TheoharidesTC. IL-1 induces vesicular secretion of IL-6 without degranulation from human mast cells. J Immunol, 171: 4830–4836, 2003.
97.
KarlssonM, LundinS, DahlgrenU, KahuH, PetterssonI, and TelemoE. “Tolerosomes” are produced by intestinal epithelial cells. Eur J Immunol, 31: 2892–2900, 2001.
98.
KarolinaDS, TavintharanS, ArmugamA, SepramaniamS, PekSL, WongMT, LimSC, SumCF, and JeyaseelanK. Circulating miRNA profiles in patients with metabolic syndrome. J Clin Endocrinol Metab, 97: E2271–E2276, 2012.
KhuntiK, DaviesM, MajeedA, ThorstedBL, WoldenML, and PaulSK. Hypoglycemia and risk of cardiovascular disease and all-cause mortality in insulin-treated people with type 1 and type 2 diabetes: a cohort study. Diabetes Care, 38: 316–322, 2015.
101.
KolbH, Kolb-BachofenV, and RoepBO. Autoimmune versus inflammatory type I diabetes: a controversy?. Immunol Today, 16: 170–172, 1995.
102.
KrogvoldL, WibergA, EdwinB, BuanesT, JahnsenFL, HanssenKF, LarssonE, KorsgrenO, SkogO, and Dahl-JørgensenK. Insulitis and characterisation of infiltrating T cells in surgical pancreatic tail resections from patients at onset of type 1 diabetes. Diabetologia, 59: 492–501, 2016.
103.
La Marca V and FierabracciA.Insights into the diagnostic potential of extracellular vesicles and their miRNA signature from liquid biopsy as early biomarkers of diabetic micro/macrovascular complications. Int J Mol Sci, 18: 1974, 2017.
104.
LakhterAJ, PrattRE, MooreRE, DoucetteKK, MaierBF, DiMeglioLA, and SimsEK. Beta cell extracellular vesicle miR-21-5p cargo is increased in response to inflammatory cytokines and serves as a biomarker of type 1 diabetes. Diabetologia, 61: 1124–1134, 2018.
105.
LeeHS, JeongJ, and LeeKJ. Characterization of vesicles secreted from insulinoma NIT-1 cells. J Proteome Res, 8: 2851–2862, 2009.
106.
LeeSI, PatelM, JonesCM, and NarendranP. Cardiovascular disease and type 1 diabetes: prevalence, prediction and management in an ageing population. Ther Adv Chronic Dis, 6: 347–374, 2015.
107.
LiQ, WangH, PengH, HuyanT, and CacalanoNA. Exosomes: versatile nano mediators of immune regulation. Cancers, 11: 1557, 2019.
108.
LiX, XieX, LianW, ShiR, HanS, ZhangH, LuL, and LiM. Exosomes from adipose-derived stem cells overexpressing Nrf2 accelerate cutaneous wound healing by promoting vascularization in a diabetic foot ulcer rat model. Exp Mol Med, 50: 1–14, 2018.
109.
LiY, LiuY, and ChuCQ. Th17 cells in type 1 diabetes: role in the pathogenesis and regulation by gut microbiome. Mediators Inflamm, 2015: 638470, 2015.
110.
LibbyP.Inflammation in atherosclerosis. Nature, 420: 868–874, 2002.
111.
LindM, SvenssonAM, KosiborodM, GudbjornsdottirS, PivodicA, WedelH, DahlqvistS, ClementsM, and RosengrenA. Glycemic control and excess mortality in type 1 diabetes. N Engl J Med, 371: 1972–1982, 2014.
112.
LiuY, MaM, YuJ, PingF, ZhangH, LiW, XuL, and LiY. Decreased serum microRNA-21, microRNA-25, microRNA-146a, and microRNA-181a in autoimmune diabetes: potential biomarkers for diagnosis and possible involvement in pathogenesis. Int J Endocrinol, 2019: 8406438, 2019.
113.
LlorenteA, SkotlandT, SylvanneT, KauhanenD, RogT, OrlowskiA, VattulainenI, EkroosK, and SandvigK. Molecular lipidomics of exosomes released by PC-3 prostate cancer cells. Biochim Biophys Acta, 1831: 1302–1309, 2013.
114.
LundbergM, SeironP, IngvastS, KorsgrenO, and SkogO. Insulitis in human diabetes: a histological evaluation of donor pancreases. Diabetologia, 60: 346–353, 2017.
115.
LuoQ, FengY, XieY, ShaoY, WuM, DengX, YuanWE, ChenY, and ShiX. Nanoparticle-microRNA-146a-5p polyplexes ameliorate diabetic peripheral neuropathy by modulating inflammation and apoptosis. Nanomedicine, 17: 188–197, 2019.
MacKenzieA, WilsonHL, Kiss-TothE, DowerSK, NorthRA, and SurprenantA. Rapid secretion of interleukin-1beta by microvesicle shedding. Immunity, 15: 825–835, 2001.
119.
MalachowskaB, WykaK, NowickaZ, BartlomiejczykMA, MlynarskiW, and FendlerW. Temporal dynamics of serum let-7g expression mirror the decline of residual beta-cell function in longitudinal observation of children with type 1 diabetes. Pediatr Diabetes, 19: 1407–1415, 2018.
120.
MarchandL, JalabertA, MeugnierE, Van den HendeK, FabienN, NicolinoM, MadecAM, ThivoletC, and RomeS. miRNA-375 a sensor of glucotoxicity is altered in the serum of children with newly diagnosed type 1 diabetes. J Diabetes Res, 2016: 1869082, 2016.
121.
MartinsB, AmorimM, ReisF, AmbrosioAF, and FernandesR. Extracellular vesicles and MicroRNA: putative Role in Diagnosis and Treatment of Diabetic Retinopathy. Antioxidants (Basel), 9: 705, 2020.
122.
MashimaR.Physiological roles of miR-155. Immunology, 145: 323–333, 2015.
123.
MazzeoA, BeltramoE, LopatinaT, GaiC, TrentoM, and PortaM. Molecular and functional characterization of circulating extracellular vesicles from diabetic patients with and without retinopathy and healthy subjects. Exp Eye Res, 176: 69–77, 2018.
124.
MazzeoA, LopatinaT, GaiC, TrentoM, PortaM, and BeltramoE. Functional analysis of miR-21-3p, miR-30b-5p and miR-150-5p shuttled by extracellular vesicles from diabetic subjects reveals their association with diabetic retinopathy. Exp Eye Res, 184: 56–63, 2019.
125.
MittalM, SiddiquiMR, TranK, ReddySP, and MalikAB. Reactive oxygen species in inflammation and tissue injury. Antioxid Redox Signal, 20: 1126–1167, 2014.
126.
MoltchanovaEV, SchreierN, LammiN, and KarvonenM. Seasonal variation of diagnosis of Type 1 diabetes mellitus in children worldwide. Diabet Med, 26: 673–678, 2009.
127.
MorelliAE, LarreginaAT, ShufeskyWJ, SullivanML, StolzDB, PapworthGD, ZahorchakAF, LogarAJ, WangZ, WatkinsSC, FaloLDJr., and ThomsonAW. Endocytosis, intracellular sorting, and processing of exosomes by dendritic cells. Blood, 104: 3257–3266, 2004.
128.
NabihES and AndrawesNG. The association between circulating levels of miRNA-181a and pancreatic beta cells dysfunction via SMAD7 in type 1 diabetic children and adolescents. J Clin Lab Anal, 30: 727–731, 2016.
129.
NakamuraM, BarberAJ, AntonettiDA, LaNoueKF, RobinsonKA, BuseMG, and GardnerTW. Excessive hexosamines block the neuroprotective effect of insulin and induce apoptosis in retinal neurons. J Biol Chem, 276: 43748–43755, 2001.
130.
NathanDM, BaylessM, ClearyP, GenuthS, Gubitosi-KlugR, LachinJM, LorenziG, and Zinman B; DCCT/EDIC ResearchGroup. Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications study at 30 years: advances and contributions. Diabetes, 62: 3976–3986, 2013.
131.
Navarro-GonzalezJF and Mora-FernandezC. The role of inflammatory cytokines in diabetic nephropathy. J Am Soc Nephrol, 19: 433–442, 2008.
132.
NazimekK, PtakW, NowakB, PtakM, AskenasePW, and BryniarskiK. Macrophages play an essential role in antigen-specific immune suppression mediated by T CD8(+) cell-derived exosomes. Immunology, 146: 23–32, 2015.
133.
NewsholmeP, KeaneKN, CarlessiR, and CruzatV. Oxidative stress pathways in pancreatic beta-cells and insulin-sensitive cells and tissues: importance to cell metabolism, function, and dysfunction. Am J Physiol Cell Physiol, 317: C420–C433, 2019.
134.
NielsenLB, WangC, SorensenK, Bang-BerthelsenCH, HansenL, AndersenML, HougaardP, JuulA, ZhangCY, PociotF, and MortensenHB. Circulating levels of microRNA from children with newly diagnosed type 1 diabetes and healthy controls: evidence that miR-25 associates to residual beta-cell function and glycaemic control during disease progression. Exp Diabetes Res, 2012: 896362, 2012.
135.
NishikawaT, KukidomeD, SonodaK, FujisawaK, MatsuhisaT, MotoshimaH, MatsumuraT, and ArakiE. Impact of mitochondrial ROS production in the pathogenesis of insulin resistance. Diabetes Res Clin Pract 77(Suppl, 1): S161–S164, 2007.
ObregonC, Rothen-RutishauserB, GitahiSK, GehrP, and NicodLP. Exovesicles from human activated dendritic cells fuse with resting dendritic cells, allowing them to present alloantigens. Am J Pathol, 169: 2127–2136, 2006.
138.
OsipovaJ, FischerDC, DangwalS, VolkmannI, WideraC, SchwarzK, LorenzenJM, SchreiverC, JacobyU, HeimhaltM, ThumT, and HaffnerD. Diabetes-associated microRNAs in pediatric patients with type 1 diabetes mellitus: a cross-sectional cohort study. J Clin Endocrinol Metab, 99: E1661–E1665, 2014.
139.
OstergaardO, NielsenCT, IversenLV, TanassiJT, KnudsenS, JacobsenS, and HeegaardNH. Unique protein signature of circulating microparticles in systemic lupus erythematosus. Arthritis Rheum, 65: 2680–2690, 2013.
140.
PadgettLE, BroniowskaKA, HansenPA, CorbettJA, and TseHM. The role of reactive oxygen species and proinflammatory cytokines in type 1 diabetes pathogenesis. Ann N Y Acad Sci, 1281: 16–35, 2013.
141.
PadgettLE, BurgAR, LeiW, and TseHM. Loss of NADPH oxidase-derived superoxide skews macrophage phenotypes to delay type 1 diabetes. Diabetes, 64: 937–946, 2015.
142.
PalmisanoG, JensenSS, Le BihanMC, LaineJ, McGuireJN, PociotF, and LarsenMR. Characterization of membrane-shed microvesicles from cytokine-stimulated beta-cells using proteomics strategies. Mol Cell Proteomics, 11: 230–243, 2012.
143.
PanBT and JohnstoneRM. Fate of the transferrin receptor during maturation of sheep reticulocytes in vitro: selective externalization of the receptor. Cell, 33: 967–978, 1983.
144.
PecheH, RenaudinK, BeriouG, MerieauE, AmigorenaS, and CuturiMC. Induction of tolerance by exosomes and short-term immunosuppression in a fully MHC-mismatched rat cardiac allograft model. Am J Transplant, 6: 1541–1550, 2006.
145.
PezzolesiMG, SatakeE, McDonnellKP, MajorM, SmilesAM, and KrolewskiAS. Circulating TGF-beta1-regulated miRNAs and the risk of rapid progression to ESRD in type 1 diabetes. Diabetes, 64: 3285–3293, 2015.
146.
PirroM, SchillaciG, PaltricciaR, BagagliaF, MenecaliC, MannarinoMR, CapanniM, VelardiA, and MannarinoE. Increased ratio of CD31+/CD42− microparticles to endothelial progenitors as a novel marker of atherosclerosis in hypercholesterolemia. Arterioscler Thromb Vasc Biol, 26: 2530–2535, 2006.
147.
PlataniaCBM, MaistoR, TrottaMC, D'AmicoM, RossiS, GesualdoC, D'AmicoG, BaltaC, HermanH, HermeneanA, FerraraccioF, PanareseI, DragoF, and BucoloC. Retinal and circulating miRNA expression patterns in diabetic retinopathy: an in silico and in vivo approach. Br J Pharmacol, 176: 2179–2194, 2019.
148.
PollackRM, DonathMY, LeRoithD, and LeibowitzG. Anti-inflammatory agents in the treatment of diabetes and its vascular complications. Diabetes Care 39(Suppl, 2): S244–S252, 2016.
149.
PrattichizzoF, de CandiaP, De NigrisV, NicolucciA, and CerielloA. Legacy effect of intensive glucose control on major adverse cardiovascular outcome: systematic review and meta-analyses of trials according to different scenarios. Metabolism, 110: 154308, 2020.
150.
PrattichizzoF, De NigrisV, MancusoE, SpigaR, GiulianiA, MatacchioneG, LazzariniR, MarcheselliF, RecchioniR, TestaR, La SalaL, RippoMR, ProcopioAD, OlivieriF, and CerielloA. Short-term sustained hyperglycaemia fosters an archetypal senescence-associated secretory phenotype in endothelial cells and macrophages. Redox Biol, 15: 170–181, 2018.
151.
PrattichizzoF, De NigrisV, SabbatinelliJ, GiulianiA, CastanoC, ParrizasM, CrespoI, GrimaldiA, BaranziniN, SpigaR, MancusoE, RippoMR, ProcopioAD, NovialsA, BonfigliAR, GaravelliS, La SalaL, MatareseG, de CandiaP, OlivieriF, and CerielloA. CD31(+) extracellular vesicles from patients with type 2 diabetes shuttle a miRNA signature associated with cardiovascular complications. Diabetes, 70: 240–254, 2021.
152.
PrattichizzoF, De NigrisV, SpigaR, MancusoE, La SalaL, AntonicelliR, TestaR, ProcopioAD, OlivieriF, and CerielloA. Inflammageing and metaflammation: the yin and yang of type 2 diabetes. Ageing Res Rev, 41: 1–17, 2018.
153.
PrattichizzoF, GiulianiA, CekaA, RippoMR, BonfigliAR, TestaR, ProcopioAD, and OlivieriF. Epigenetic mechanisms of endothelial dysfunction in type 2 diabetes. Clin Epigenetics, 7: 56, 2015.
154.
PrattichizzoF, GiulianiA, De NigrisV, PujadasG, CekaA, La SalaL, GenoveseS, TestaR, ProcopioAD, OlivieriF, and CerielloA. Extracellular microRNAs and endothelial hyperglycaemic memory: a therapeutic opportunity?. Diabetes Obes Metab, 18: 855–867, 2016.
155.
PrattichizzoF, MatacchioneG, GiulianiA, SabbatinelliJ, OlivieriF, de CandiaP, De NigrisV, and CerielloA. Extracellular vesicle-shuttled miRNAs: a critical appraisal of their potential as nano-diagnostics and nano-therapeutics in type 2 diabetes mellitus and its cardiovascular complications. Theranostics, 11: 1031–1045, 2021.
156.
PrestonRA, JyW, JimenezJJ, MauroLM, HorstmanLL, ValleM, AimeG, and AhnYS. Effects of severe hypertension on endothelial and platelet microparticles. Hypertension, 41: 211–217, 2003.
157.
PuaHH, SteinerDF, PatelS, GonzalezJR, Ortiz-CarpenaJF, KageyamaR, ChiouNT, GallmanA, de KouchkovskyD, JekerLT, McManusMT, ErleDJ, and AnselKM. MicroRNAs 24 and 27 suppress allergic inflammation and target a network of regulators of T helper 2 cell-associated cytokine production. Immunity, 44: 821–832, 2016.
158.
QuY, FranchiL, NunezG, and DubyakGR. Nonclassical IL-1 beta secretion stimulated by P2X7 receptors is dependent on inflammasome activation and correlated with exosome release in murine macrophages. J Immunol, 179: 1913–1925, 2007.
159.
RahmanMJ, RegnD, BashratyanR, and DaiYD. Exosomes released by islet-derived mesenchymal stem cells trigger autoimmune responses in NOD mice. Diabetes, 63: 1008–1020, 2014.
160.
RangasamyS, McGuirePG, Franco NittaC, MonickarajF, OrugantiSR, and DasA. Chemokine mediated monocyte trafficking into the retina: role of inflammation in alteration of the blood-retinal barrier in diabetic retinopathy. PLoS One, 9: e108508, 2014.
161.
RaposoG, NijmanHW, StoorvogelW, LiejendekkerR, HardingCV, MeliefCJ, and GeuzeHJ. B lymphocytes secrete antigen-presenting vesicles. J Exp Med, 183: 1161–1172, 1996.
162.
RaposoG and StoorvogelW. Extracellular vesicles: exosomes, microvesicles, and friends. J Cell Biol, 200: 373–383, 2013.
163.
RawshaniA, RawshaniA, FranzenS, EliassonB, SvenssonAM, MiftarajM, McGuireDK, SattarN, RosengrenA, and GudbjornsdottirS. Mortality and cardiovascular disease in type 1 and type 2 diabetes. N Engl J Med, 376: 1407–1418, 2017.
164.
ReissAB, VerniceNA, SiegartNM, De LeonJ, and KasselmanLJ. Exosomes in cholesterol metabolism and atherosclerosis. Cardiovasc Hematol Disord Drug Targets, 17: 185–194, 2017.
165.
RoepBO, AtkinsonM, and von HerrathM. Satisfaction (not) guaranteed: re-evaluating the use of animal models of type 1 diabetes. Nat Rev Immunol, 4: 989–997, 2004.
166.
RoggliE, GattescoS, CailleD, BrietC, BoitardC, MedaP, and RegazziR. Changes in microRNA expression contribute to pancreatic β-cell dysfunction in prediabetic NOD mice. Diabetes, 61: 1742–1751, 2012.
167.
RomioM, ReinbeckB, BongardtS, HulsS, BurghoffS, and SchraderJ. Extracellular purine metabolism and signaling of CD73-derived adenosine in murine Treg and Teff cells. Am J Physiol Cell Physiol, 301: C530–C539, 2011.
168.
RutmanAK, NegiS, GasparriniM, HasiloCP, TchervenkovJ, and ParaskevasS. Immune response to extracellular vesicles from human islets of langerhans in patients with type 1 diabetes. Endocrinology, 159: 3834–3847, 2018.
169.
SabatierF, DarmonP, HugelB, CombesV, SanmarcoM, VelutJG, ArnouxD, CharpiotP, FreyssinetJM, OliverC, SampolJ, and Dignat-GeorgeF. Type 1 and type 2 diabetic patients display different patterns of cellular microparticles. Diabetes, 51: 2840–2845, 2002.
170.
SalemMA, AdlyAA, IsmailEA, DarwishYW, and KamelHA. Platelets microparticles as a link between micro- and macro-angiopathy in young patients with type 1 diabetes. Platelets, 26: 682–688, 2015.
171.
SamandariN, MirzaAH, NielsenLB, KaurS, HougaardP, FredheimS, MortensenHB, and PociotF. Circulating microRNA levels predict residual beta cell function and glycaemic control in children with type 1 diabetes mellitus. Diabetologia, 60: 354–363, 2017.
172.
SangalliE, TagliabueE, SalaL, PrattichizzoF, UccellatoreA, SpadaD, LorinoF, de CandiaP, LupiniS, CantoneL, FaveroC, MadedduP, BollatiV, GenoveseS, and SpinettiG. Circulating microRNA-15a associates with retinal damage in patients with early stage type 2 diabetes. Front Endocrinol (Lausanne), 11: 254, 2020.
173.
SantosAS, Cunha NetoE, FukuiRT, FerreiraLRP, and SilvaMER. Increased expression of circulating microRNA 101–103p in type 1 diabetes patients: new insights into miRNA-regulated pathophysiological pathways for type 1 diabetes. Front Immunol, 10: 1637, 2019.
174.
SatakeE, PezzolesiMG, Md DomZI, SmilesAM, NiewczasMA, and KrolewskiAS. Circulating miRNA profiles associated with hyperglycemia in patients with type 1 diabetes. Diabetes, 67: 1013–1023, 2018.
175.
SchofieldJ, HoJ, and SoranH. Cardiovascular risk in type 1 diabetes mellitus. Diabetes Ther, 10: 773–789, 2019.
176.
SecrestAM, BeckerDJ, KelseySF, LaporteRE, and OrchardTJ. Cause-specific mortality trends in a large population-based cohort with long-standing childhood-onset type 1 diabetes. Diabetes, 59: 3216–3222, 2010.
177.
SeguraE, NiccoC, LombardB, VeronP, RaposoG, BatteuxF, AmigorenaS, and TheryC. ICAM-1 on exosomes from mature dendritic cells is critical for efficient naive T-cell priming. Blood, 106: 216–223, 2005.
178.
SemeraroF, CancariniA, dell'OmoR, RezzolaS, RomanoMR, and CostagliolaC. Diabetic retinopathy: vascular and inflammatory disease. J Diabetes Res, 2015: 582060, 2015.
179.
ShakerOG, AbdelaleemOO, MahmoudRH, AbdelghaffarNK, AhmedTI, SaidOM, and ZakiOM. Diagnostic and prognostic role of serum miR-20b, miR-17-3p, HOTAIR, and MALAT1 in diabetic retinopathy. IUBMB Life, 71: 310–320, 2019.
180.
ShengH, HassanaliS, NugentC, WenL, Hamilton-WilliamsE, DiasP, and DaiYD. Insulinoma-released exosomes or microparticles are immunostimulatory and can activate autoreactive T cells spontaneously developed in nonobese diabetic mice. J Immunol, 187: 1591–1600, 2011.
181.
Shigemoto-KurodaT, OhJY, KimDK, JeongHJ, ParkSY, LeeHJ, ParkJW, KimTW, AnSY, ProckopDJ, and LeeRH. MSC-derived extracellular vesicles attenuate immune responses in two autoimmune murine models: type 1 diabetes and uveoretinitis. Stem Cell Reports, 8: 1214–1225, 2017.
182.
SmythLA, RatnasothyK, TsangJY, BoardmanD, WarleyA, LechlerR, and LombardiG. CD73 expression on extracellular vesicles derived from CD4+ CD25+ Foxp3+ T cells contributes to their regulatory function. Eur J Immunol, 43: 2430–2440, 2013.
183.
SpectreG, MobarrezF, StalesenR, OstensonCG, VaronD, WallenH, and HjemdahlP. Meal intake increases circulating procoagulant microparticles in patients with type 1 and type 2 diabetes mellitus. Platelets, 30: 348–355, 2019.
184.
SteffesMW, SibleyS, JacksonM, and ThomasW. Beta-cell function and the development of diabetes-related complications in the Diabetes Control and Complications Trial. Diabetes Care, 26: 832–836, 2003.
185.
StoorvogelW, KleijmeerMJ, GeuzeHJ, and RaposoG. The biogenesis and functions of exosomes. Traffic, 3: 321–330, 2002.
186.
StrandbergTE, SalomaaVV, VanhanenHT, NaukkarinenVA, SarnaSJ, and MiettinenTA. Mortality in participants and non-participants of a multifactorial prevention study of cardiovascular diseases: a 28 year follow up of the Helsinki Businessmen Study. Br Heart J, 74: 449–454, 1995.
187.
SukK, KimS, KimYH, KimKA, ChangI, YagitaH, ShongM, and LeeMS. IFN-gamma/TNF-alpha synergism as the final effector in autoimmune diabetes: a key role for STAT1/IFN regulatory factor-1 pathway in pancreatic beta cell death. J Immunol, 166: 4481–4489, 2001.
188.
SunYM, SuY, LiJ, and WangLF. Recent advances in understanding the biochemical and molecular mechanism of diabetic nephropathy. Biochem Biophys Res Commun, 433: 359–361, 2013.
189.
TerrazzanoG, BruzzanitiS, RubinoV, SantopaoloM, PalatucciAT, GiovazzinoA, La RoccaC, de CandiaP, PucaA, PernaF, ProcacciniC, De RosaV, PorcelliniC, De SimoneS, FattorussoV, PorcelliniA, MozzilloE, TronconeR, FranzeseA, LudvigssonJ, MatareseG, RuggieroG, and GalganiM. T1D progression is associated with loss of CD3(+)CD56(+) regulatory T cells that control CD8(+) T cell effector functions. Nat Metab, 2: 142–152, 2020.
190.
TesovnikT, KovacJ, PoharK, HudoklinS, DovcK, BratinaN, Trebusak PodkrajsekK, DebeljakM, VeranicP, BosiE, PiemontiL, IhanA, and BattelinoT. Extracellular vesicles derived human-miRNAs modulate the immune system in type 1 diabetes. Front Cell Dev Biol, 8: 202, 2020.
191.
TestaR, BonfigliAR, PrattichizzoF, La SalaL, De NigrisV, and CerielloA. The “metabolic memory”. theory and the early treatment of hyperglycemia in prevention of diabetic complications. Nutrients, 9: 437, 2017.
192.
ThayerTC, DelanoM, LiuC, ChenJ, PadgettLE, TseHM, AnnamaliM, PiganelliJD, MoldawerLL, and MathewsCE. Superoxide production by macrophages and T cells is critical for the induction of autoreactivity and type 1 diabetes. Diabetes, 60: 2144–2151, 2011.
193.
TheryC, BoussacM, VeronP, Ricciardi-CastagnoliP, RaposoG, GarinJ, and AmigorenaS. Proteomic analysis of dendritic cell-derived exosomes: a secreted subcellular compartment distinct from apoptotic vesicles. J Immunol, 166: 7309–7318, 2001.
ThomouT, MoriMA, DreyfussJM, KonishiM, SakaguchiM, WolfrumC, RaoTN, WinnayJN, Garcia-MartinR, GrinspoonSK, GordenP, and KahnCR. Adipose-derived circulating miRNAs regulate gene expression in other tissues. Nature, 542: 450–455, 2017.
196.
TorriA, CarpiD, BulgheroniE, CrostiMC, MoroM, GruarinP, RossiRL, RossettiG, Di VizioD, HoxhaM, BollatiV, GaglianiC, TacchettiC, ParoniM, GeginatJ, CortiL, VenegoniL, BertiE, PaganiM, MatareseG, AbrignaniS, and de CandiaP. Extracellular microRNA signature of human helper T cell subsets in health and autoimmunity. J Biol Chem, 292: 2903–2915, 2017.
197.
TrajkovicK, HsuC, ChiantiaS, RajendranL, WenzelD, WielandF, SchwilleP, BrüggerB, and SimonsM. Ceramide triggers budding of exosome vesicles into multivesicular endosomes. Science, 319: 1244–1247, 2008.
198.
TsukitaS, YamadaT, TakahashiK, MunakataY, HosakaS, TakahashiH, GaoJ, ShiraiY, KodamaS, AsaiY, SugisawaT, ChibaY, KanekoK, UnoK, SawadaS, ImaiJ, and KatagiriH. MicroRNAs 106b and 222 improve hyperglycemia in a mouse model of insulin-deficient diabetes via pancreatic beta-cell proliferation. EBioMedicine, 15: 163–172, 2017.
199.
TurchinovichA, SamatovTR, TonevitskyAG, and BurwinkelB. Circulating miRNAs: cell-cell communication function?. Front Genet, 4: 119, 2013.
200.
TurpinD, TruchetetM-E, FaustinB, AugustoJ-F, Contin-BordesC, BrissonA, BlancoP, and DuffauP. Role of extracellular vesicles in autoimmune diseases. Autoimmun Rev, 15: 174–183, 2016.
201.
ValadiH, EkstromK, BossiosA, SjostrandM, LeeJJ, and LotvallJO. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol, 9: 654–659, 2007.
202.
van de BuntM, GaultonKJ, PartsL, MoranI, JohnsonPR, LindgrenCM, FerrerJ, GloynAL, and McCarthyMI. The miRNA profile of human pancreatic islets and beta-cells and relationship to type 2 diabetes pathogenesis. PLoS One, 8: e55272, 2013.
203.
van der WerfN, KroeseFG, RozingJ, and HillebrandsJL. Viral infections as potential triggers of type 1 diabetes. Diabetes Metab Res Rev, 23: 169–183, 2007.
204.
VasavadaN and AgarwalR. Role of oxidative stress in diabetic nephropathy. Adv Chronic Kidney Dis, 12: 146–154, 2005.
205.
VenceL, BenoistC, and MathisD. Fas deficiency prevents type 1 diabetes by inducing hyporesponsiveness in islet beta-cell-reactive T-cells. Diabetes, 53: 2797–2803, 2004.
206.
WahlgrenJ, Karlson TdeL, GladerP, TelemoE, and ValadiH. Activated human T cells secrete exosomes that participate in IL-2 mediated immune response signaling. PLoS One, 7: e49723, 2012.
207.
WangP, ChenF, WangW, and ZhangXD. Hydrogen sulfide attenuates high glucose-induced human retinal pigment epithelial cell inflammation by inhibiting ROS formation and NLRP3 inflammasome activation. Mediators Inflamm, 2019: 8908960, 2019.
208.
WangX, GuH, HuangW, PengJ, LiY, YangL, QinD, EssandohK, WangY, PengT, and FanGC. Hsp20-mediated activation of exosome biogenesis in cardiomyocytes improves cardiac function and angiogenesis in diabetic mice. Diabetes, 65: 3111–3128, 2016.
209.
WillcoxA, RichardsonSJ, BoneAJ, FoulisAK, and MorganNG. Analysis of islet inflammation in human type 1 diabetes. Clin Exp Immunol, 155: 173–181, 2009.
210.
WitwerKW and TheryC. Extracellular vesicles or exosomes?. On primacy, precision, and popularity influencing a choice of nomenclature. J Extracell Vesicles, 8: 1648167, 2019.
211.
WuX, GaoY, XuL, DangW, YanH, ZouD, ZhuZ, LuoL, TianN, WangX, TongY, and HanZ. Exosomes from high glucose-treated glomerular endothelial cells trigger the epithelial-mesenchymal transition and dysfunction of podocytes. Sci Rep, 7: 9371, 2017.
212.
WuXM, GaoYB, CuiFQ, and ZhangN. Exosomes from high glucose-treated glomerular endothelial cells activate mesangial cells to promote renal fibrosis. Biol Open, 5: 484–491, 2016.
213.
XiaY, XieZ, HuangG, and ZhouZ. Incidence and trend of type 1 diabetes and the underlying environmental determinants. Diabetes Metab Res Rev, 35: e3075, 2019.
214.
XiaoC and RajewskyK. MicroRNA control in the immune system: basic principles. Cell, 136: 26–36, 2009.
215.
XieY, ZhangH, LiW, DengY, MunegowdaMA, ChibbarR, QureshiM, and XiangJ. Dendritic cells recruit T cell exosomes via exosomal LFA-1 leading to inhibition of CD8+ CTL responses through downregulation of peptide/MHC class I and Fas ligand-mediated cytotoxicity. J Immunol, 185: 5268–5278, 2010.
216.
YamagishiS, FukamiK, UedaS, and OkudaS. Molecular mechanisms of diabetic nephropathy and its therapeutic intervention. Curr Drug Targets, 8: 952–959, 2007.
217.
YamagishiS, UedaS, MatsuiT, NakamuraK, and OkudaS. Role of advanced glycation end products (AGEs) and oxidative stress in diabetic retinopathy. Curr Pharm Des, 14: 962–968, 2008.
218.
YingW, RiopelM, BandyopadhyayG, DongY, BirminghamA, SeoJB, OfrecioJM, WollamJ, Hernandez-CarreteroA, FuW, LiP, and OlefskyJM. Adipose tissue macrophage-derived exosomal miRNAs can modulate in vivo and in vitro insulin sensitivity. Cell, 171: 372.e12–384.e12, 2017.
219.
YuL, YangF, JiangL, ChenY, WangK, XuF, WeiY, CaoX, WangJ, and CaiZ. Exosomes with membrane-associated TGF-beta1 from gene-modified dendritic cells inhibit murine EAE independently of MHC restriction. Eur J Immunol, 43: 2461–2472, 2013.
220.
ZampetakiA, WilleitP, BurrS, YinX, LangleySR, KiechlS, KleinR, RossingP, ChaturvediN, and MayrM. Angiogenic microRNAs linked to incidence and progression of diabetic retinopathy in type 1 diabetes. Diabetes, 65: 216–227, 2016.
221.
ZhangHG, LiuC, SuK, YuS, ZhangL, ZhangS, WangJ, CaoX, GrizzleW, and KimberlyRP. A membrane form of TNF-alpha presented by exosomes delays T cell activation-induced cell death. J Immunol, 176: 7385–7393, 2006.
222.
ZhangW, DongX, WangT, and KongY. Exosomes derived from platelet-rich plasma mediate hyperglycemia-induced retinal endothelial injury via targeting the TLR4 signaling pathway. Exp Eye Res, 189: 107813, 2019.
223.
ZhaoS, LiT, LiJ, LuQ, HanC, WangN, QiuQ, CaoH, XuX, ChenH, and ZhengZ. miR-23b-3p induces the cellular metabolic memory of high glucose in diabetic retinopathy through a SIRT1-dependent signalling pathway. Diabetologia, 59: 644–654, 2016.
224.
ZhengB, YinWN, SuzukiT, ZhangXH, ZhangY, SongLL, JinLS, ZhanH, ZhangH, LiJS, and WenJK. Exosome-mediated miR-155 transfer from smooth muscle cells to endothelial cells induces endothelial injury and promotes atherosclerosis. Mol Ther, 25: 1279–1294, 2017.
225.
ZieglerAG, HummelM, SchenkerM, and BonifacioE. Autoantibody appearance and risk for development of childhood diabetes in offspring of parents with type 1 diabetes: the 2-year analysis of the German BABYDIAB Study. Diabetes, 48: 460–468, 1999.
226.
ZieglerD, AmetovA, BarinovA, DyckPJ, GurievaI, LowPA, MunzelU, YakhnoN, RazI, NovosadovaM, MausJ, and SamigullinR. Oral treatment with alpha-lipoic acid improves symptomatic diabetic polyneuropathy: the SYDNEY 2 trial. Diabetes Care, 29: 2365–2370, 2006.
227.
ZomerA, MaynardC, Verweij FrederikJ, KamermansA, SchäferR, BeerlingE, Schiffelers RaymondM, de WitE, BerenguerJ, Ellenbroek Saskia IngeJ, WurdingerT, Pegtel DirkM, and van RheenenJ. In vivo imaging reveals extracellular vesicle-mediated phenocopying of metastatic behavior. Cell, 161: 1046–1057, 2015.
